Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

One thing we could say about the analysts on Hansa Biopharma AB (publ) (STO:HNSA) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. Bidders are definitely seeing a different story, with the stock price of kr32.20 reflecting a 11% rise in the past week. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.

After the downgrade, the four analysts covering Hansa Biopharma are now predicting revenues of kr209m in 2024. If met, this would reflect a major 56% improvement in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 35% to kr10.32 per share. Yet before this consensus update, the analysts had been forecasting revenues of kr265m and losses of kr10.34 per share in 2024. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady.

See our latest analysis for Hansa Biopharma

The consensus price target was broadly unchanged at kr110, implying that the business is performing roughly in line with expectations, despite a downwards adjustment to forecast sales this year.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Hansa Biopharma'shistorical trends, as the 56% annualised revenue growth to the end of 2024 is roughly in line with the 66% annual revenue growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 15% annually. So it's pretty clear that Hansa Biopharma is forecast to grow substantially faster than its industry.

The Bottom Line

While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on Hansa Biopharma after today.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Hansa Biopharma analysts - going out to 2026, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.